Latanoprost/timolol
| Combination of | |
|---|---|
| Latanoprost | Prostaglandin |
| Timolol | Beta blocker |
| Clinical data | |
| Trade names | Xalacom |
| Routes of administration | Eye drops |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| PubChem CID | |
| KEGG | |
| CompTox Dashboard (EPA) | |
Latanoprost/timolol, sold under the brand name Xalacom, is a combination drug used for the treatment of glaucoma, consisting of latanoprost (increase uveoscleral outflow of aqueous humor[3]) and timolol (a beta blocker decreasing the production of aqueous fluid).
Society and culture
[edit]Brand names
[edit]In some countries, Xalacom is marketed by Viatris after Upjohn was spun off from Pfizer.[4][5]
References
[edit]- ↑ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
- ↑ "Summary of Product Characteristics (SmPC)". (emc). 13 June 2022. Retrieved 31 March 2024.
- ↑ Patel SS, Spencer CM (1996). "Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension". Drugs Aging. 9 (5): 363–378. doi:10.2165/00002512-199609050-00007. PMID 8922563. S2CID 25169085.
- ↑ "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024 – via Business Wire.
- ↑ "Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.
 | This pharmacology-related article is a stub. You can help Wikipedia by adding missing information. |